Brickell Biotech, Inc. BBI

This company will do a reverse split soon so they offering it down and will offering again to .25$ then 1:20 reverse split

More shares added

Lot of positive news patient approved and huge catalyst s from analysts with an average of $5.5.

We are going to fly soon.

Lake Street Capital initiated Brickell Biotech (BBI +17.2%) with a Buy rating and price target of $6 indicating more than five-folds increase from current levels.
Analyst Thomas Flaten believes that the company has rapidly advanced its lead development program to Phase 3 readiness since becoming public via a reverse merger in 2019.
He further adds that he likes the odds of Brickell's treatment of primary axillary hyperhidrosis taking on Eli Lilly's Qbrexza in serving an underappreciated and under-treated disease state affecting a population of ~10M in the U.S.
Investor Presentation of Brickell states that it expects to initiate pivotal Phase 3 program in Q4; also there is a significant U.S. market opportunity in Hyperhidrosis which affects ~ 4.8% (15.3M) of U.S. population. $BBI

Lake Street Capital initiated Brickell Biotech (BBI +17.2%) with a Buy rating and price target of $6 indicating more than five-folds increase from current levels.
Analyst Thomas Flaten believes that the company has rapidly advanced its lead development program to Phase 3 readiness since becoming public via a reverse merger in 2019.
He further adds that he likes the odds of Brickell's treatment of primary axillary hyperhidrosis taking on Eli Lilly's Qbrexza in serving an underappreciated and under-treated disease state affecting a population of ~10M in the U.S.
Investor Presentation of Brickell states that it expects to initiate pivotal Phase 3 program in Q4; also there is a significant U.S. market opportunity in Hyperhidrosis which affects ~ 4.8% (15.3M) of U.S. population. $BBI

Lake Street Capital initiated Brickell Biotech (BBI +17.2%) with a Buy rating and price target of $6 indicating more than five-folds increase from current levels.
Analyst Thomas Flaten believes that the company has rapidly advanced its lead development program to Phase 3 readiness since becoming public via a reverse merger in 2019.
He further adds that he likes the odds of Brickell's treatment of primary axillary hyperhidrosis taking on Eli Lilly's Qbrexza in serving an underappreciated and under-treated disease state affecting a population of ~10M in the U.S.
Investor Presentation of Brickell states that it expects to initiate pivotal Phase 3 program in Q4; also there is a significant U.S. market opportunity in Hyperhidrosis which affects ~ 4.8% (15.3M) of U.S. population. $BBI

Lol Monday the votes will get result of 50 mils more shares add, this one going below .70$ good luck as holding bags

Any positive news ... to fly some.....?

Toasted turd sandwich this thing